Arthritis care & research

Factors linked to knee joint damage and symptoms from early arthritis to joint replacement

Updated

Abstract

More than half of the knees with no/mild radiographic osteoarthritis progressed to severe radiographic osteoarthritis during a 4-year follow-up.

  • Of the knees with no/mild radiographic osteoarthritis at baseline, 51.0% progressed to severe osteoarthritis.
  • Knees with no/mild radiographic osteoarthritis showed significantly higher odds of bone marrow lesions in the patellofemoral joint at both baseline and before knee replacement.
  • The odds of developing pain from baseline to the time before knee replacement were 5.48 times higher in knees with no/mild radiographic osteoarthritis compared to those with severe osteoarthritis.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Conflict of Interest Statement . Frank W. Roemer: CMO and Shareholder Boston Imaging Core Lab. (BICL), LLC. C. Kent Kwoh: Research grants to the University of Arizona by Abbvie and EMD Serono (>$10,000). Consultant for Thusane, EMD Serono, Astellas (all < $10,000). Tomoko Fujii: No financial disclosures. Michael J. Hannon: Consultant to EMD Serono (> $10,000). Robert M. Boudreau: No financial disclosures. David J. Hunter: Consultant to Merck Serono, TissueGene and Flexion (all < $10,000). Felix Eckstein: CEO and shareholder of Chondrometrics GmbH and consultant to Merck Serono, Samumed, Abbvie, Bioclinica and Servier (all < $10,000). Markus R. John: full time employee by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Ali Guermazi: President of Boston Imaging Core Lab, LLC, and consultant to Merck Serono and Pfizer (>$10,000), Tissue Gene, OrthoTrophix, GE, Sanofi and Astra Zeneca (<$10,000)
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free